119-39-1 = 86-54-4 反应条件:1.1 Reagents: Phosphorus Oxychloride; 2 Min,Rt2.1 Reagents: Hydrazine Hydrate (1:1) Solvents: Ethanol; 1 H,Rt 标题:Identification Of New Potent Phthalazine Derivatives With Vegfr-2 And Egfr Kinase Inhibitory Activity 作者:Amin,Kamilia M.; Et Al 参考文献:European Journal Of Medicinal Chemistry 日期:2016 卷标:123 页码:191-201]
119-39-1 = 86-54-4 反应条件:1.1 Reagents: Phosphorus Oxychloride Solvents: Dichloromethane; 40 - 50 °C2.1 Reagents: Hydrazine Hydrate (1:1) Solvents: Ethanol; 78 °C 标题:1,2,3-Triazolyl Pyrazole Derivatives As Anti-Cancer Agents: Biological Evaluation And Molecular Docking 作者:Bhat,Manjunatha; Et Al 参考文献:Pharma Chemica 日期:2016 卷标:8(19) 页码:200-221]
119-67-5 = 86-54-4 [标题:Reaction Conditions 标题:Product Class 10: Phthalazines 作者:Haider,N.; Et Al 参考文献:Science Of Synthesis 日期:2004 卷标:16 页码:315-372]
2741-57-3 = 86-54-4 [标题:Reaction Conditions 标题:Product Class 10: Phthalazines 作者:Haider,N.; Et Al 参考文献:Science Of Synthesis 日期:2004 卷标:16 页码:315-372]
88491-65-0 = 86-54-4 反应条件:1.1 Reagents: Hydrazine Solvents: Ethanol 标题:Sn(Anrorc) Mechanism. Part 31. Hydrazination Of Pyridazines And Phthalazines 作者:Counotte-Potman,A.; Et Al 参考文献:Journal Of Heterocyclic Chemistry 日期:1983 卷标:20(5) 页码:1259-61]
253-52-1 = 86-54-4 反应条件:1.1 Reagents: Trichloroisocyanuric Acid Solvents: Dimethylformamide; 4 H,Rt -> 50 °C2.1 Reagents: Hydrazine Hydrate (1:1) Solvents: Ethanol; 5 H,Reflux 标题:Synthesis And In Vitro Evaluation Of Hydrazinyl Phthalazines Against Malaria Parasite,Plasmodium Falciparum 作者:Subramanian,Gowtham; Et Al 参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2016 卷标:26(14) 页码:3300-3306]
119-67-5 = 86-54-4 反应条件:1.1 Reagents: Hydrazine Hydrate (1:1); 1 H,Rt2.1 Reagents: Phosphorus Oxychloride; 2 Min,Rt3.1 Reagents: Hydrazine Hydrate (1:1) Solvents: Ethanol; 1 H,Rt 标题:Identification Of New Potent Phthalazine Derivatives With Vegfr-2 And Egfr Kinase Inhibitory Activity 作者:Amin,Kamilia M.; Et Al 参考文献:European Journal Of Medicinal Chemistry 日期:2016 卷标:123 页码:191-201]
3260-44-4 = 86-54-4 [标题:Reaction Conditions 标题:Product Class 10: Phthalazines 作者:Haider,N.; Et Al 参考文献:Science Of Synthesis 日期:2004 卷标:16 页码:315-372]
480-91-1 = 86-54-4 [标题:Reaction Conditions 标题:Product Class 10: Phthalazines 作者:Haider,N.; Et Al 参考文献:Science Of Synthesis 日期:2004 卷标:16 页码:315-372
专利号:US-10925977-B2 优先权日:2006-10-05 标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications 发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S 权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS 摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.
专利号:US-2008287407-A1 优先权日:2003-12-10 标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use 发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI 权利人:NITROMED INC 摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.
专利号:US-7708989-B2 优先权日:1999-10-29 标题 :Methods of treating vascular diseases characterized by nitric oxide insufficiency 发明人:LOSCALZO JOSEPH; VITA JOSEPH A; LOBERG MICHAEL D; WORCEL MANUEL 权利人:NITROMED INC 摘要:The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and/or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The vascular diseases characterized by nitric oxide insufficiency include a cardiovascular disease and a disease resulting from oxidative stress.
专利号:US-7220858-B2 优先权日:2003-12-23 标 题 :Synthesis of hydrazine and chlorinated derivatives of bicyclic pyridazines 发明人:NELSON DEANNA J 权利人:BARBEAU PHARMA INC 摘要:The present invention relates to both a novel method of preparing hydralazine hydrochloride and to a novel method of preparing hydrazine derivatives of compounds containing a pyridazine ring, including, for example, pyridazines, phthalazines and other compounds containing the pyridazine ring.
专利号:US-2008125354-A1 优先权日:2005-11-21 标题 :Selective inhibition of matrix metalloproteinases 发明人:FIELDS GREGG B; HAMMER ROBERT 权利人:UNIV FLORIDA ATLANTIC; UNIV LOUISIANA STATE 摘要:Synthetic triple-helical peptides (THPs) are used for the design and synthesis of triple-helical transition state analog inhibitors. These inhibitors feature a phosphonate ester or phosphinic moiety in place of the scissle bond. These groups inhibit MMPs, and methods been developed for their convenient incorporation within a peptide sequence by solid-phase methods.
专利号:US-8278296-B2 优先权日:2006-08-10 标题:Manipulation of brain CDP-diacylglycerol and uses thereof 发明人:UNDIEH ASHIWEL S 权利人:UNDIEH ASHIWEL S 摘要:Provided herein methods of screening for potential antidepressant compounds effective to increase production of cellular CDP-diacylglycerol and synthesis of inositol phospholipid in depression-related areas of the brain. Also, provided are methods of diagnosing and treating depressive or mood disorders in a subject by administering these screened antidepressant compounds. Further provided is a method of determining the therapeutic efficacy of an antidepressant drug regimen by comparing the ratio of CDP-diacylglycerol/inositol phosphate after treatment to a basal ratio in a subject.
1: Nyolczas N, Dékány M, Muk B, Szabó B. Combination of Hydralazine and Isosorbide-Dinitrate in the Treatment of Patients with Heart Failure with Reduced Ejection Fraction. Adv Exp Med Biol. 2018;1067:31-45. doi: 10.1007/5584_2017_112. Review. doi: 10.1002/ar.23618. Epub 2017 Jul 25. doi: 10.1371/journal.pone.0158010. eCollection 2016. 4: Flynn JT, Bradford MC, Harvey EM. Intravenous Hydralazine in Hospitalized Children and Adolescents with Hypertension. J Pediatr. 2016 Jan;168:88-92. doi: 10.1016/j.jpeds.2015.07.070. Epub 2015 Sep 1. doi: 10.1097/MJT.0000000000000310. doi: 10.1007/s00467-014-2772-0. Epub 2014 Feb 20.
合成参考文献
参考文献:10.1007/s10165-010-0272-z|10.3109/s10165-010-0272-z 摘要:Matsuki Y, Sato K, Fujikawa A, Kyoto Y, Hashimoto H, Hakozaki Y. A case of incidentally detected IgG4-related sclerosing disease involving inflammatory abdominal aortic aneurysm and autoimmune pancreatitis. Mod Rheumatol. 2010 Jun;20(3):306–10. doi: 10.1007/s10165-010-0272-z. 参考文献:10.1038/labinvest.2011.92 摘要:Kao YH, Cheng CC, Chen YC, Chung CC, Lee TI, Chen SA, Chen YJ. Hydralazine-induced promoter demethylation enhances sarcoplasmic reticulum Ca2+ -ATPase and calcium homeostasis in cardiac myocytes. Lab Invest. 2011 Sep;91(9):1291–7. doi: 10.1038/labinvest.2011.92. 参考文献:10.1007/s12028-011-9593-9 摘要:Wolf S; Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Routine management of volume status after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2011 Sep;15(2):275–80. doi: 10.1007/s12028-011-9593-9. 参考文献:10.1186/1472-6963-11-167 摘要:de Vries AE, de Jong RM, van der Wal MH, Jaarsma T, van Dijk RB, Hillege HL. The value of INnovative ICT guided disease management combined with Telemonitoring in OUtpatient clinics for Chronic Heart failure patients. Design and methodology of the IN TOUCH study: a multicenter randomised trial. BMC Health Services Research. 2011 Jul 13;11(1):167. doi: 10.1186/1472-6963-11-167. 参考文献:10.1007/s00467-011-1964-0 摘要:Chandar J, Zilleruelo G. Hypertensive crisis in children. Pediatr Nephrol. 2012 May;27(5):741–51. doi: 10.1007/s00467-011-1964-0.